Jenny Qian

Jenny Qian is an accomplished biostatistician with extensive experience in managing statistical aspects of clinical trials across various therapeutic areas, including Parkinson’s disease, Alzheimer's, and multiple sclerosis. Currently serving as Executive Director of Biostatistics and Programming at Xenon Pharmaceuticals Inc., Jenny has successfully overseen the progression of numerous Phase I-III trials and contributed to obtaining recent NDA and EMA approvals for an inhaled Parkinson's drug. Prior roles include Senior Director at Cara Therapeutics and Director at Acorda Therapeutics, reflecting a robust career that began as a Statistical Analyst at Eli Lilly and Company. Jenny holds a Master's degree in Biostatistics from the UCLA Fielding School of Public Health.